214 results on '"Khan, Cyrus"'
Search Results
2. Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
3. Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
4. Consolidative Autologous Stem Cell Transplantation Versus Whole Brain Radiation in PCNSL; a Nationwide Analysis
5. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
6. Successful Treatment of Refractory Post-Transplant Lymphoproliferative Disorder With Chimeric Antigen Receptor T-Cell Therapy in a Heart Transplant Recipient
7. Outcomes of Patients Initiated on Ruxolitinib As Second Line Treatment of aGVHD: A Single Institution Experience
8. POSTER: ABCL-478 Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study
9. ABCL-478 Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study
10. P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY
11. Primary Testicular Lymphoma: Single Center Experience
12. Chronic Lymphocytic Leukemia: Rapidly Changing Treatment Landscape
13. Does low-grade follicular lymphoma with high proliferation index require a different treatment strategy? A single center experience.
14. Incidence of malignant pericardial effusion in pericardiocentesis patients and post-procedure care: an oncology center pilot study
15. A Meningioma Mimic and Distinct Subtype of Primary Central Nervous System Lymphoma: Primary Dural Lymphoma
16. Primary Dural Lymphoma Case Report: A Distinct Subtype of Primary Central Nervous System Lymphoma
17. Impact of Absolute Lymphocyte Count (ALC) and Pre-Transplant Prealbumin Level on Engraftment, Acute Graft Versus Host Disease (GVHD) and Mortality Following Allogeneic Hematopoietic Cell Transplantation: A Single Institution Experience
18. Likelihood of Successful Mobilization with Cyclophosphamide after Failure of Growth Factor Mobilization in Patients with Multiple Myeloma
19. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
20. Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment
21. A Case of Primary Dural Lymphoma Treated with Bendamustine and Rituxan
22. Venetoclax-induced vitiligo in a patient with chronic lymphocytic leukemia
23. ABCL-340 Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume
24. Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume
25. Intrathecal Chemotherapy as a Potential Treatment for Steroid-refractory Immune Effector Cell-associated Neurotoxicity Syndrome
26. Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.
27. Predictors and Long-Term Outcomes for Diffuse Large B-Cell Lymphoma (DLBCL) Patients Undergoing Surgery Prior to Systemic Therapy: A Nationwide Analysis
28. The Trend of Combined Modality Treatment and its Outcomes in Elderly Patients With Primary CNS Lymphoma: A 12-year Population-based Analysis Using Propensity Score
29. Impact of Infused CD34+ Stem Cell Dosing for Allogeneic Peripheral Blood Stem Transplantation with Post-Transplant Cyclophosphamide; A Quality Assurance Study
30. Utilization of Hematopoietic Progenitor Cells (HPC) Stored for Future Salvage Auto Transplant or Stem Cell Boost for Patients Diagnosed with Multiple Myeloma and Its Cost Implications
31. Reduced Intensity Conditioning (Fludarabine and Busulfan) for Allogeneic Hematopoietic Cell Transplantation in Patients with Severe Aplastic Anemia
32. Does Renal Impairment Affect Survival Outcomes for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation with Melphalan Conditioning?
33. Does Post-Transplant Cyclophosphamide Increase Early Cardiac Toxicity in Allogeneic Stem Cell Transplantation: A Single Center Experience
34. Efficacy of Sars-Cov-2 Vaccine in Hematopoietic Stem Cell Transplantation and CAR-T Cell Therapy Patients; A Single Study Experience
35. Treatment Outcomes for Follicular Lymphoma with Progression of Disease within 24 Months of Front-Line Therapy: A Systematic Review
36. Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)
37. Oral Abstract: ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)
38. Poster:ABCL-360 Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)
39. ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)
40. Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
41. The Trend of Combined Modality Treatment and its Outcomes in Elderly Patients With Primary CNS Lymphoma; A 12-Year Population-Based Analysis Using Propensity Score
42. Autologous stem cell transplantation (ASCT) versus whole brain radiation (WBRT) as a consolidation therapy in primary CNS lymphoma (PCNSL): A nationwide analysis.
43. G-CSF Administration Post Transplant Does Not Accelerate Neutrophil Engraftment or Delay Platelet Engraftment in Recipients Undergoing Auto-HCT Regardless of CD34 Dose
44. Impact of Pre-Transplant Disease Status on Survival Outcomes in Patients with Multiple Myeloma Undergoing Auto-HCT
45. Abbreviated Cryotherapy for Mucositis Prevention Is As Effective As Caphosol in Patients with Multiple Myeloma Undergoing Auto-HCT with Melphalan Conditioning
46. Comparison of Two Different Doses of Anti-Thymocyte Globulin in Preventing GVHD Based on Recipient Absolute Lymphocyte Count
47. Flubutbi Versus BEAM As the Conditioning Regimen before Autologous Hematopoietic Stem Cell Transplantation in Lymphoid Malignancies
48. Rare Oral Presentation of a Mycophenolate Mofetil-Related Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorder (MMF-OIA-LPD) Lesion: A Case Report and Literature Review
49. Predictors and Long Term Outcomes for DLBCL Patients Undergoing Surgery Prior to Systemic Therapy
50. 366 - Impact of Absolute Lymphocyte Count (ALC) and Pre-Transplant Prealbumin Level on Engraftment, Acute Graft Versus Host Disease (GVHD) and Mortality Following Allogeneic Hematopoietic Cell Transplantation: A Single Institution Experience
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.